Skip to main content

Table 1 Retreatment with ICP inhibitors in metastatic melanoma

From: Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

 

Ipi → Ipi

Ipi + Nivo→Nivo

 

Robert et al. [5] (n = 38)

Chiarion-Sileni et al [7] (n = 51)

Lebbe et al [10] (n = 122)

Pollack et al [8] (n = 80)

ORR (%)

18.4

11.8

23.0

70.0

DCR (%)

60.5

54.9

48.4

88.8

All grade irAE (%)

57.9

21.6

64.0

50.0

Grade 3/4 irAE (%)

10.5

13.5

13.5

30.0

  1. Ipi ipilimumab, Nivo nivolumab, ORR overall response rate, DCR disease control rate, irAE immune-related adverse event
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us